Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / Mapp Biopharmaceutical / Gilead Sciences

Mapp Biopharmaceutical & Gilead Sciences

2 shared events · Importance 3 · Last updated Jul 05, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (2)
65
Tech
Ebola Treatment Trial Begins DRC
Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, an experimental monoclonal antibody treatment being tested in the Ebola clinical trial. The United States government has funded research for this drug.
Gilead Sciences: Gilead Sciences is the developer of remdesivir, one of the antiviral drugs being evaluated in the clinical trial for Ebola. The company has donated doses of the drug for the study.
Apr 20, 2026 · 67 articles
30
Tech
WHO Lists Bundibugyo Ebola Test
Mapp Biopharmaceutical: Mapp Biopharmaceutical's experimental MBP134 antibody is being evaluated in a treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, either as a standalone treatment or in combination with Gilead Sciences' remdesivir.
Gilead Sciences: Gilead Sciences' antiviral drug remdesivir is being evaluated in combination with Mapp Biopharmaceutical's MBP134 antibody in a treatment trial for the Bundibugyo Ebola outbreak.
Jul 02, 2026 · 8 articles
NEWSDESK
Explore this relationship live

Track how Mapp Biopharmaceutical and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.